New Delhi: BioAsia 2026, Asia’s premier life sciences and healthcare forum, is set to convene global scientific pioneers, artificial intelligence leaders, industry CEOs, and policymakers at a pivotal moment for healthcare innovation.
Scheduled for February 17–18, 2026, the conference will focus on the theme “TechBio Unleashed: AI, Automation & the Biology Revolution,” examining how artificial intelligence, advanced biology, and intelligent manufacturing are reshaping the way therapies are discovered, developed, and delivered worldwide.
As biology becomes increasingly programmable and AI continues to compress research, development, and manufacturing timelines, the TechBio paradigm is moving rapidly from experimentation to real-world execution. BioAsia 2026 aims to capture this transition by bringing together leaders building AI-driven discovery platforms, next-generation biologics, and digitally integrated healthcare operating models.
The conference will open with inaugural addresses by A. Revanth Reddy, Chief Minister of Telangana, and D. Sridhar Babu, Minister for Information Technology, Electronics, Communications, Industries and Commerce, reaffirming Telangana’s ambition to position Hyderabad among the world’s top five life sciences hubs. A dedicated session titled “Telangana Rising Vision 2047” will outline the state’s long-term roadmap for innovation-led growth in AI-enabled R&D, advanced therapeutics, and next-generation biomanufacturing.
BioAsia 2026 will feature a distinguished lineup of global leaders from science, AI, and biopharma. Dr. Stefan Miltenyi, Founder and President of Miltenyi Biotec, will discuss the evolution of next-generation biologics from discovery to scalable manufacturing. Dr. Howard Y. Chang, Chief Scientific Officer at Amgen, will explore how AI-powered biology is transforming target discovery and precision medicine. Representing the frontier of artificial intelligence, Pushmeet Kohli, Vice President of Science at Google DeepMind, will share insights on foundational models, protein science breakthroughs, and reinforcement learning in biological discovery.
On the operational and industry transformation front, Madeleine Roach of Sanofi will speak about the company’s AI-first transformation across R&D and manufacturing, while Anton Groom, Chief AI Officer at MSD, will discuss embedding AI into pharmaceutical R&D workflows. Despina Solomonidou of Novartis will highlight digital and automation-led pharmaceutical development models, and Rashmi Kumar, CIO of Medtronic, will focus on AI-driven digital transformation in MedTech. Manufacturing innovation will be addressed by Eamonn Warren of Eli Lilly, and AI-enabled diagnostics transformation by Badhri Srinivasan, Group CEO of Unilabs.
Across nine thematic sessions, BioAsia 2026 will bring together leaders from global pharmaceutical and biotechnology companies including Amgen, Novartis, Lilly, Medtronic, Sanofi, Roche, AbbVie, Bristol Myers Squibb, AstraZeneca, Novo Nordisk, Takeda, MSD, Lonza, Thermo Fisher Scientific, and Miltenyi Biotec. Indian industry leaders from organisations such as Dr. Reddy’s Laboratories, Bharat Biotech, Biocon Biologics, Zydus Lifesciences, Laurus Labs, Sai Life Sciences, Aragen, Piramal Pharma, Syngene, TCS, and Apollo Hospitals will also participate.
Discussions will focus on scaling innovation across science, software, and supply chains; growth drivers and structural challenges for pharma and biotech between 2026 and 2030; AI-enabled CRDMO and biomanufacturing ecosystems; and the development of advanced biologics from discovery to manufacturing readiness. A CEO Conclave will bring global industry leaders together to discuss geopolitics, resilience, and innovation pathways shaping the sector’s future.
The second day will highlight the rapid evolution of Global Capability Centres (GCCs) in life sciences, which are increasingly emerging as strategic innovation hubs rather than cost-efficiency centres. Sessions will explore AI-enabled R&D, digital transformation, financing TechBio innovation, and scaling deep-tech manufacturing from India to global markets.
By bringing together global pioneers, policymakers, investors, and innovators, BioAsia 2026 aims to strengthen collaboration across the TechBio ecosystem while reinforcing Hyderabad’s growing stature as a global centre for biotechnology, pharmaceuticals, and digital health innovation.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: biovoicenews.com
